Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 12 Mar 24 424B3 Prospectus supplement
- 1 Mar 24 424B3 Prospectus supplement
- 12 Feb 24 424B3 Prospectus supplement
- 1 Feb 24 424B3 Prospectus supplement
- 23 Jan 24 424B3 Prospectus supplement
- 22 Jan 24 EFFECT Notice of effectiveness
- 16 Jan 24 S-1/A IPO registration (amended)
- 10 Jan 24 UPLOAD Letter from SEC
- 8 Jan 24 S-1/A IPO registration (amended)
- 21 Dec 23 UPLOAD Letter from SEC
- 12 Dec 23 S-1/A IPO registration (amended)
- 19 Oct 23 UPLOAD Letter from SEC
-
5 Oct 23 S-1 IPO registration
CLDI similar filings
Filing view
External links
EXHIBIT 23.3
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the inclusion in this Registration Statement on Form S-1 and related prospectus of our report dated March 16, 2022, with respect to the consolidated financial statements of Calidi Biotherapeutics, Inc. (Company) as of December 31, 2021 and for the year then ended (which report includes an explanatory paragraph regarding the existence of substantial doubt about the Company’s ability to continue as a going concern), and to the reference to us under the heading “Experts” in the prospectus which is part of this Registration Statement.
/s/ Mayer Hoffman McCann P.C.
San Diego, California
October 5, 2023